AmbioPharm is a private peptide CDMO in North Augusta, South Carolina. Learn what it makes for US pharma clients and why it has no stock ticker.
AmbioPharm is a privately held contract development and manufacturing organization (CDMO) that produces synthetic peptides for pharmaceutical and biotechnology companies. The company is headquartered in North Augusta, South Carolina, and operates business-to-business rather than selling finished products to individual consumers. That single distinction explains most of the confusion surrounding the AmbioPharm name in search results.
What AmbioPharm Does
AmbioPharm makes peptide active pharmaceutical ingredients (APIs) and provides the services that surround them, from process development through commercial-scale manufacturing. Drug developers hire a CDMO like AmbioPharm when they need a peptide produced under current Good Manufacturing Practice (cGMP) conditions rather than as a laboratory research chemical.
Core service areas include:
- Custom peptide synthesis at scales ranging from grams to multi-kilogram batches.
- Process development and scale-up for peptides moving from lab bench to commercial production.
- Analytical testing and quality control that supports regulatory filings.
- Regulatory documentation, including drug master file support for client submissions.
Most ambiopharm peptides are manufactured for pharmaceutical clients that plan to file them with regulators, which is why quality systems and documentation matter as much as synthesis chemistry. The company also works on generic peptides, where patent expirations open marketed drugs to additional manufacturers.
Who AmbioPharm Serves — and Who It Does Not
AmbioPharm's customers are drug developers, biotech companies, generic manufacturers, and research organizations. These are buyers who need supply agreements, facility audits, and long-term capacity planning, not single vials shipped to a home address.
AmbioPharm does not sell peptides to consumers and does not operate a retail storefront. If you see ambiopharm peptide for sale on a consumer website or marketplace app, that listing is not an authorized AmbioPharm sales channel, and the product's origin, purity, and sterility are unknown.
That matters for safety. Peptides labeled for research use only are not evaluated by the FDA for human use, and injectable products from unverified sellers have been tied to sterility failures and dosing errors. Anyone considering a peptide for a health condition should speak with a licensed healthcare professional rather than buying from an unregulated source.
AmbioPharm and GLP-1 Peptides Like Tirzepatide
Interest in ambiopharm tirzepatide grew alongside the broader GLP-1 boom. Tirzepatide is a synthetic peptide, and peptide CDMOs are the facilities that manufacture peptides of this type at commercial scale on behalf of drug sponsors.
Tirzepatide is marketed by Eli Lilly under brand names and is available in the United States only by prescription. A CDMO's ability to synthesize a peptide does not make unapproved versions of that peptide legal or safe, and research-grade tirzepatide sold online is not FDA-approved.
A quick comparison of who supplies what:
| Supplier type | Who can buy | Regulatory status | Typical use |
|---|---|---|---|
| Peptide CDMO (AmbioPharm) | Pharma and biotech companies under contract | Facilities inspected; client products regulated as drugs | Manufacturing peptide APIs for approved or investigational drugs |
| Prescription pharmacy | Patients with a valid prescription | Approved or compounded under state and federal rules | Treatment under medical supervision |
| Online research peptide seller | Anyone with a credit card | Not FDA-approved | Labeled for research; not for human use |
AmbioPharm Stock, Revenue, and Employees
Searches for ambiopharm stock reflect a common misunderstanding. AmbioPharm is a private company, so there is no ticker symbol, no quarterly earnings call, and no SEC filing history for investors to review.
Because AmbioPharm is privately held, revenue and headcount figures are not published in audited public statements. Third-party business databases publish estimates, but those figures vary between providers and should be treated as approximations rather than confirmed financials.
| Company fact | Detail |
|---|---|
| Headquarters | North Augusta, South Carolina |
| Ownership | Privately held |
| Publicly traded | No — no stock ticker exists |
| Primary business | Peptide API development and cGMP manufacturing |
| Main customer base | Pharmaceutical, biotech, and generic drug companies |
Investors sometimes confuse AmbioPharm with publicly traded peptide and CDMO companies, so verifying the legal name behind a ticker is the fastest way to avoid that mistake.
AmbioPharm Jobs and Careers
People searching for ambiopharm jobs usually find openings in manufacturing, quality control, analytical chemistry, process engineering, and supply chain. Peptide production is a specialized field, so employers often look for chromatography experience, cGMP familiarity, and chemistry or biochemistry degrees.
Most roles sit at the North Augusta, South Carolina site, and hiring tends to track demand for peptide APIs. Candidates should apply through the company's official careers page or verified job boards rather than responding to unsolicited recruiter messages.
Why Peptide Manufacturing Capacity Matters
Peptide drugs have moved from niche products to mainstream medicine, and GLP-1 medications are a large part of that shift. The demand surge has tightened global manufacturing capacity and pushed CDMOs to invest in new suites and larger reactors.
Industry reporting points to US capacity expansion across peptide manufacturers, including AmbioPharm, as companies respond to GLP-1 demand. For drug developers, the practical takeaway is that capacity, timelines, and quality systems drive supplier selection as much as price per gram.
Key Takeaways
- AmbioPharm is a private peptide CDMO based in North Augusta, South Carolina.
- AmbioPharm does not sell peptides to individual consumers.
- AmbioPharm has no stock ticker because it is not a publicly traded company.
- Tirzepatide is a prescription drug, and research-grade versions sold online are not FDA-approved.
- Anyone considering peptide therapy should consult a licensed healthcare professional.
Frequently Asked Questions
Is AmbioPharm a publicly traded company?
No. AmbioPharm is a privately held company, so there is no AmbioPharm stock ticker and no SEC filings for investors to review. Search results for AmbioPharm stock often point to unrelated publicly traded peptide or CDMO companies instead.
Does AmbioPharm sell peptides to individuals?
AmbioPharm is a business-to-business peptide CDMO, and it does not sell peptides directly to consumers. Listings describing AmbioPharm peptides for sale on consumer websites are not authorized AmbioPharm channels. Peptides sold that way are typically labeled for research use only and are not FDA-approved for human use.
Does AmbioPharm make tirzepatide?
AmbioPharm is a peptide manufacturer with the capability to produce GLP-1 peptides as active pharmaceutical ingredients for drug sponsors. Tirzepatide itself is marketed by Eli Lilly and is legally available in the US only by prescription. Research-grade tirzepatide sold online is not FDA-approved for human use.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.